BRPI0511054A - uso de dipiridamola para o tratamento de resistência a inibidores plaquetários - Google Patents
uso de dipiridamola para o tratamento de resistência a inibidores plaquetáriosInfo
- Publication number
- BRPI0511054A BRPI0511054A BRPI0511054-8A BRPI0511054A BRPI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- resistance
- treatment
- platelet
- dipyridamole
- Prior art date
Links
- 239000000106 platelet aggregation inhibitor Substances 0.000 title abstract 5
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002768 dipyridamole Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 5
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 108090000672 Annexin A5 Proteins 0.000 abstract 1
- 102000004121 Annexin A5 Human genes 0.000 abstract 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 229940122388 Thrombin inhibitor Drugs 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 abstract 1
- 229960003856 argatroban Drugs 0.000 abstract 1
- 229960001500 bivalirudin Drugs 0.000 abstract 1
- 108010055460 bivalirudin Proteins 0.000 abstract 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 abstract 1
- -1 bivalrudine Chemical compound 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000003055 low molecular weight heparin Substances 0.000 abstract 1
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003868 thrombin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE DIPIRIDAMOLA PARA O TRATAMENTO DE RESISTêNCIA A INIBIDORES PLAQUETáRIOS. A presente invenção refere-se a um método de tratamento de resistência a inibidores plaquetários, isto é, um método para superar a resistência de tratamento com inibidores plaquetários, o referido método compreendendo administração de uma quantidade terapeuticamente eficaz de dipiridamola em combinação com um inibidor plaquetário e, opcionalmente, em combinação com um terceiro componente antitrombótico, tal como inibidores diretos de trombina, inibidores de fator Xa, inibidores combinados de trombina/fator Xa, heparina, heparina de baixo peso molecular, argatroban, bivalrudina, hirulog ou poliglicanas a um paciente que precisa do mesmo. A invenção ainda se refere ao uso de dipiridamola para a fabricação de uma composição farmacêutica para o tratamento de resistência a inibidores plaquetários. A invenção também se refere a um método para diagnosticar a resistência ao tratamento com inibidores plaquetários, o referido método compreendendo medição da densidade de ligação de Anexina V sobre plaquetas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57059704P | 2004-05-13 | 2004-05-13 | |
| PCT/EP2005/005024 WO2005113006A2 (en) | 2004-05-13 | 2005-05-10 | Use of dipyridamole for treatment of resistance to platelet inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511054A true BRPI0511054A (pt) | 2007-11-27 |
Family
ID=34969445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511054-8A BRPI0511054A (pt) | 2004-05-13 | 2005-05-10 | uso de dipiridamola para o tratamento de resistência a inibidores plaquetários |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090048173A1 (pt) |
| EP (1) | EP1747016A2 (pt) |
| JP (1) | JP2007537184A (pt) |
| KR (1) | KR20070026577A (pt) |
| CN (1) | CN101068570A (pt) |
| AU (1) | AU2005245271A1 (pt) |
| BR (1) | BRPI0511054A (pt) |
| CA (1) | CA2566081A1 (pt) |
| IL (1) | IL179169A0 (pt) |
| MX (1) | MXPA06013157A (pt) |
| RU (1) | RU2006143838A (pt) |
| WO (1) | WO2005113006A2 (pt) |
| ZA (1) | ZA200609058B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| WO2006045756A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| AU2012214396B2 (en) * | 2011-02-09 | 2017-04-27 | Chiesi Farmaceutici S.P.A. | Methods for treating pulmonary hypertension |
| US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US20150306281A1 (en) * | 2014-04-28 | 2015-10-29 | Nalini Marie Rajamannan | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| TW201503900A (zh) | 2013-07-29 | 2015-02-01 | ren-zheng Lin | 增強治療急性中風之抗血小板藥物之遞送方法及其組合物 |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| EP3096748B1 (en) | 2014-01-24 | 2019-09-25 | The Arizona Board of Regents on behalf of the University of Arizona | Methods for altering shear force-induced platelet activation |
| EP3283012A4 (en) * | 2015-04-15 | 2018-11-21 | Concievalve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| CN104965017B (zh) * | 2015-06-17 | 2017-06-16 | 广西师范学院 | 水蛭素抗凝血酶活性的测定方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US176469A (en) * | 1876-04-25 | Improvement in carpet-beaters | ||
| US175831A (en) * | 1876-04-11 | Improvement in jig-saw attachments | ||
| US151595A (en) * | 1874-06-02 | Improvement in hand corn-planters | ||
| US107409A (en) * | 1870-09-13 | Improvement in double-shovel plows | ||
| US183519A (en) * | 1876-10-24 | Improvement in cornice-gutters | ||
| US77729A (en) * | 1868-05-12 | William hall | ||
| US151534A (en) * | 1874-06-02 | Improvement in | ||
| US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| US5498613A (en) * | 1994-06-07 | 1996-03-12 | The University Of Southern California | Dipyridamole and analogs thereof in preventing adhesion formation |
| FR2728901B1 (fr) * | 1994-12-28 | 1997-03-28 | Sanofi Sa | Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6136794A (en) * | 1998-02-02 | 2000-10-24 | Merck & Co., Inc. | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2000035859A1 (de) * | 1998-12-16 | 2000-06-22 | Boehringer Ingelheim Pharma Kg | Substituierte aryl- und heteroarylderivate, deren herstellung und deren verwendung als arzneimittel |
| EP1093814A1 (en) | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| WO2001031052A1 (en) * | 1999-10-25 | 2001-05-03 | Colorado Coagulation Consultants | Thromboxane b2 metabolite and methods for regulating aspirin-related platelet action |
| FR2809181B1 (fr) * | 2000-05-16 | 2002-10-25 | Biocytex | Monoreactif pour le dosage des microparticules plaquettaires |
| US8519005B2 (en) * | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| WO2002059623A2 (en) * | 2001-01-24 | 2002-08-01 | Sendx Medical, Inc. | Methods for determining platelet activity with antiplatelet compositions |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| AU2004231306A1 (en) | 2003-04-24 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
-
2005
- 2005-05-10 JP JP2007512064A patent/JP2007537184A/ja active Pending
- 2005-05-10 US US11/568,730 patent/US20090048173A1/en not_active Abandoned
- 2005-05-10 AU AU2005245271A patent/AU2005245271A1/en not_active Abandoned
- 2005-05-10 WO PCT/EP2005/005024 patent/WO2005113006A2/en not_active Ceased
- 2005-05-10 CN CNA2005800236935A patent/CN101068570A/zh active Pending
- 2005-05-10 BR BRPI0511054-8A patent/BRPI0511054A/pt not_active IP Right Cessation
- 2005-05-10 MX MXPA06013157A patent/MXPA06013157A/es not_active Application Discontinuation
- 2005-05-10 RU RU2006143838/14A patent/RU2006143838A/ru not_active Application Discontinuation
- 2005-05-10 KR KR1020067026148A patent/KR20070026577A/ko not_active Withdrawn
- 2005-05-10 EP EP05748279A patent/EP1747016A2/en not_active Withdrawn
- 2005-05-10 CA CA002566081A patent/CA2566081A1/en not_active Abandoned
-
2006
- 2006-10-31 ZA ZA200609058A patent/ZA200609058B/en unknown
- 2006-11-09 IL IL179169A patent/IL179169A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005113006A2 (en) | 2005-12-01 |
| KR20070026577A (ko) | 2007-03-08 |
| CN101068570A (zh) | 2007-11-07 |
| RU2006143838A (ru) | 2008-06-20 |
| IL179169A0 (en) | 2007-03-08 |
| ZA200609058B (en) | 2008-03-26 |
| MXPA06013157A (es) | 2007-02-13 |
| WO2005113006A3 (en) | 2007-02-08 |
| US20090048173A1 (en) | 2009-02-19 |
| EP1747016A2 (en) | 2007-01-31 |
| JP2007537184A (ja) | 2007-12-20 |
| AU2005245271A1 (en) | 2005-12-01 |
| CA2566081A1 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511054A (pt) | uso de dipiridamola para o tratamento de resistência a inibidores plaquetários | |
| NZ591057A (en) | Complement antagonists and uses thereof | |
| BRPI0611717A2 (pt) | composto, composiÇço farmacÊutica e uso do composto | |
| ECSP088503A (es) | COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS | |
| BRPI0905369B8 (pt) | composição farmacêutica, uso da composição farmacêutica e kit compartimentado | |
| BR112014013377A2 (pt) | filme em multicamada livre de camada de metal com baixo peso superficial | |
| BR0213817A (pt) | Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9 | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| CY1116064T1 (el) | Συστασεις αναστολεα ddp iv | |
| BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
| BR112017002527A2 (pt) | revestimentos de artigos incluindo camada de polifenol oligomerizado e métodos biológicos de uso | |
| BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
| BR112015020209A2 (pt) | uso de linagliptina em terapia antidiabética de proteção cardíaca e renal | |
| ATE526942T1 (de) | Hydroalkoholische antimikrobielle zusammensetzung mit vorteilen für gesunde haut | |
| BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
| BR112012011485A2 (pt) | "composições e métodos para tratar náusea e vômito centralmente mediados". | |
| BR112013029269A2 (pt) | "combinação farmacêutica para uso na melhora da tolerância à glicose em pacientes com diabetes tipo 2 e o uso da mesma". | |
| BRPI0713447A2 (pt) | composição forma de dosagem oral sólida, e, método para o tratamento de dor | |
| BRPI0905687A2 (pt) | "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto" | |
| BR0010380A (pt) | Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos | |
| DE602004004817D1 (de) | Myo-inositol hexaphosphat zur topischen verwendung | |
| CY1114045T1 (el) | Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |